Considering the abnormalities of SOCS1 expression in damaged tissues, as well as its role in the regulation of downstream cytokines, SOCS1 may be a novel therapeutic target in the treatment of patients with SLE. This evidence concerns the gene SOCS1 and systemic lupus erythematosus.